OptiNose Company Overview
About OptiNose
OptiNose (NASDAQ:OPTN) is a specialized healthcare company focused on developing and commercializing innovative products for patients with ear, nose, throat (ENT), and allergy conditions. Its pioneering technology, based on Exhalation Delivery Systems (EDS), aims to significantly improve the delivery and effectiveness of medical treatments. The company's flagship product is a novel nasal spray designed for superior drug delivery to targeted sites within the nasal cavity. OptiNose's project pipeline also includes therapies for conditions such as chronic sinusitis and nasal polyps, demonstrating its commitment to addressing unmet medical needs in the ENT space. Striving to improve quality of life for patients through more effective treatments, OptiNose is actively working on expanding its portfolio through research and collaboration, aiming to become a key player in respiratory and allergy therapeutics.
Snapshot
Operations
Products and/or services of OptiNose
- XHANCE (fluticasone propionate) nasal spray, a treatment for chronic sinusitis and nasal polyps.
- Development of OPN-019, combines XHANCE technology with an antiseptic for potential COVID-19 therapeutic applications.
- Research into additional uses of exhalation delivery system for treating ear, nose, and throat diseases.
- Partnership programs for the development and commercialization of products using their patented bi-directional breath powered delivery technology.
- Innovations in drug delivery mechanisms aimed at improving efficacy and patient experience for intranasal therapies.
- Collaborations with pharmaceutical companies to expand the reach and application of their nasal drug delivery technology.
OptiNose executive team
- Dr. Ramy A. Mahmoud M.D., M.P.H.CEO & Director
- Mr. Michael F. Marino Esq.Chief Legal Officer & Corporate Secretary
- Mr. Paul SpenceChief Commercial Officer
- Mr. P. Terence KohlerChief Financial Officer
- Mr. Anthony J. KrickVP of Finance & Chief Accounting Officer
- Mr. Jonathan NeelyVice President of Investor Relations & Business Development
- Ms. Karen E. BrophyChief Human Resources Officer & VP of Human Resources